Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Biolidics Ltd. (8YY) Share Price & Analysis

8YY Stock Chart & Stats

SGD 0.02-SGD 0.00(-7.69%)
At close: 5:00 PM GMT+8
SGD 0.025SGD 0.03SGD 0.035SGD 0.043 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
SGD 0.02 - SGD 0.03
52-Week Range
SGD 0.02 - SGD 0.09
Previous Close
SGD 0.03
Volume
13.75M
Average Volume (3M)
612.98K
Market Cap
SGD 41.60M
Enterprise Value
SGD 74.41M
Total Cash (Recent Filing)
SGD 494.00K
Total Debt (Recent Filing)
SGD 2.77M
Price to Earnings (P/E)
―
Beta
0.45
Next Earnings
Nov 04, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Rebound

The sharp 2025 revenue rebound indicates renewed demand or improved commercialization after a very low prior-year base. If maintained, stronger sales could improve operating leverage, support broader customer adoption, and create a foundation for the diagnostics business to scale over the next several quarters.

Recurring Diagnostic Consumables

Selling assays, kits, and per-test consumables gives the company a product model linked to ongoing diagnostic usage rather than only one-time equipment sales. Greater clinical or laboratory adoption could therefore generate repeat purchasing and deepen customer relationships over time.

Balance-Sheet Repair

The return to positive equity represents a degree of balance-sheet repair compared with the negative-equity periods in 2022 and 2023. Although the cushion remains modest, restoring positive net worth may provide a more stable base for commercialization and future operating improvement.

Bears Say

Persistent Losses

Persistent operating and net losses show that the revenue rebound has not yet translated into a sustainable earnings model. Continued losses can consume capital, restrict investment in product commercialization, and leave the company dependent on future improvement before it can fund growth internally.

Negative Cash Generation

Repeatedly negative operating and free cash flow indicates that the business is not yet self-funding, even after the 2025 improvement from the prior year. Ongoing cash outflows may require external funding or balance-sheet resources, limiting flexibility to invest through a longer commercialization cycle.

Leverage And Thin Equity Cushion

Debt is substantial relative to the company’s modest equity base, while the history of negative equity highlights balance-sheet fragility. This structure can constrain strategic choices, increase pressure to improve operations quickly, and reduce resilience if losses or cash outflows persist.

Biolidics Ltd. News

8YY FAQ

What was Biolidics Ltd.’s price range in the past 12 months?
Biolidics Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Biolidics Ltd.’s market cap?
Biolidics Ltd.’s market cap is S$41.60M.
When is Biolidics Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Biolidics Ltd.’s earnings last quarter?
Biolidics Ltd. released its earnings results on Aug 12, 2026. The company reported S$0 earnings per share for the quarter.
Is Biolidics Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Biolidics Ltd. pay dividends?
Biolidics Ltd. does not currently pay dividends.
What is Biolidics Ltd.’s EPS estimate?
Biolidics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biolidics Ltd. have?
Biolidics Ltd. has 1,733,441,800 shares outstanding.
What happened to Biolidics Ltd.’s price movement after its last earnings report?
Biolidics Ltd. reported an EPS of S$0 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biolidics Ltd.?
Currently, no hedge funds are holding shares in SG:8YY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology